Health Canada has authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

COVID-19 vaccine-associated myocarditis (C-VAM) has a mild initial clinical course, but myocardial injury is common, ...

Florida officials are issuing conflicting statements with the Centers for Disease Control and Prevention about COVID-19 ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Chaffee County, CO - Chaffee County Public Health (CCPH) has been preparing for another active respiratory illness season and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...